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Abstract
Background: The goal of our study was to molecularly dissect mesothelioma tumour pathways by mean of microarray
technologies in order to identify new tumour biomarkers that could be used as early diagnostic markers and possibly as
specific molecular therapeutic targets.
Methodology: We performed Affymetrix HGU133A plus 2.0 microarray analysis, containing probes for about 39,000 human
transcripts, comparing 9 human pleural mesotheliomas with 4 normal pleural specimens. Stringent statistical feature
selection detected a set of differentially expressed genes that have been further evaluated to identify potential biomarkers
to be used in early diagnostics. Selected genes were confirmed by RT-PCR. As reported by other mesothelioma profiling
studies, most of genes are involved in G2/M transition. Our list contains several genes previously described as prognostic
classifier. Furthermore, we found novel genes, never associated before to mesotheliom that could be involved in tumour
progression. Notable is the identification of MMP-14, a member of matrix metalloproteinase family. In a cohort of 70
mesothelioma patients, we found by a multivariate Cox regression analysis, that the only parameter influencing overall
survival was expression of MMP14. The calculated relative risk of death in MM patients with low MMP14 expression was
significantly lower than patients with high MMp14 expression (P=0.002).
Conclusions: Based on the results provided, this molecule could be viewed as a new and effective therapeutic target to test
for the cure of mesothelioma.
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Introduction
Malignant mesothelioma (MM) is a rare, highly aggressive
tumour that arises from the surface serosal cells (pleural, peritoneal
and pericardial cavities). Epidemiological and clinical data show
that there is an association between asbestos exposure and MM
development [1], even if the exact mechanism whereby asbestos
induces MM is unknown [2,3]. Western countries delayed in
applying prevention measures connected to the risk of asbestos and
this will produce a global increase of MM in the next years. This
pathology has a long latency but a very short survival; until now
the small number of drugs used for MM therapeutic treatment,
does not seem to provide any clear advantage if used in different
combinations or as monotherapy [4]. The prognosis is generally
poor with a reported median survival of 4 to 12 months in either
untreated or treated patients. Moreover, the reported response
rate to the different therapeutic protocols ranged from 10% to
45% with no clear advantage in terms of poor survival (4–9
months). Currently, the trimodality approach - that employs
extrapleural pneumonectomy followed by combination of che-
moradiotherapy - is applied [5]. Moreover, the combination of
chemotherapy followed by surgery supplemented by postoperative radiotherapy
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and Pass, 2008). Recent randomized studies on treatment of MM with
combined chemotherapy demonstrate a survival benefit when a combination of
cisplatin and antifolate drugs has been used (Fennell et al., 2008). A combined
treatment, using the COX-inhibitors piroxicam with cisplatin, was recently
tested in a murine orthotopic model of MM, showing an anti-tumour effects
with survival increasing [6,7]. Another promising pre-clinical study, based on
a combined treatment with cisplatin and the proteasome inhibitor Bortezomib,
showed an apoptosis increasing in MM cell lines [8].
Until now the molecular bases that induce MM development
are still unknown; moreover, to make a precise diagnosis invasive
techniques like thoracoscopy or biopsy are used, since no putative
biomarkers have been clearly defined for this deadly disease, and
actually the available MM biomarkers shows some limitations [9].
Indeed, the long incubation period of asbestos-related MM
development, implies that the malignant transformation is related
to different and multiple genetic changes. Microarray technology
leads to perform transcriptomic analysis and correlates variations
in the gene expression with cellular and physiological state; this is
important because all processes determining variations in gene
expression can give support to malignant transformation [10]. It is
emerging that in MM the discovery of new diagnostic biomarkers
is needed to achieve improved early diagnosis, in order to apply, in
a selective way, multimodal therapy as in a pre-clinical stage or
before definitive surgery. This makes the survival time increase
(from 11 months to 5 years in epithelial MM) [11]. Moreover, the
identification of tumour biomarkers could greatly facilitate
surveillance procedures for all the cohorts of patients exposed to
asbestos, a phenomenon common in different areas of the western
countries, such as different in zones of Italy [12].
In the last year microarray analyses, have contributed to shed light in
understanding the molecular basis of MM development and progression. The
global number of MM samples profiled is growing-up but yet is quite low - in
comparison with other tumours - mainly because the low incidence of MM and
the difficulty of retry large numbers of tumour samples.
These analyses reported deregulation of different genes involved in mitotic
checkpoint that might have a key role in MM development and maintenance.
Furthermore the identified genes were used to generate predictive gene-list.
A profiling of 21 MM tumours was used to generate a 27-gene neural
network classifier to discriminate patients in short-term and long-term
survivors [13]. A subsequent profiling of 31 MM samples was used to
develop first a 22-gene list that was reduced to a non-overlapping 7-gene list
used to derive prognostic predictors of 1-year survival. [14,15]. More
recently two different large transcriptional profiling led to identify new genes
allowing to discriminate tumour tissues from normal [16], or allowing to
predict a 1-year survival [17].
The goal of our study was the molecular dissection of MM
tumour pathways by mean of microarray technology in order to
identify new tumour biomarkers, which could be used as early
diagnostic markers or as new specific therapeutic targets. To this
end, we used Affymetrix technology to identify genes differently
expressed between normal and MM patient pleural tissues. Our
analysis confirmed some previously described differences in expression patterns.
In addition, we identified and validated, for the first time, the
different expression level of some genes during MM progression.
In conclusion, our analysis allowed us to identify a series of novel
progression-associated changes in gene expression, and to confirm,
at the same time, a number of previously described results.
Methods
Tissue acquisition for microarray
Subjects selected for the analysis were 9 patients, consecutively
treated at the Department of Thoracic Surgery of the Second
University of Naples from 2004 to 2005, underwent a standard
thoracotomy for therapeutic reasons (Table 1).
MM tissue was obtained from those patients with a confirmed
pathological diagnosis and who had not received prior therapy.
Intraoperative malignant mesothelial samples and nodules were
dissected from associated fat and connective tissue, but no
microdissection was performed. H&E staining was performed to
verify the presence of neoplastic cells and to determine the
histological subtype. Samples were stored in RNAlater (Ambion)
following the manufacturer’s protocol until RNA extraction.
Control pleural tissue was obtained from patients undergoing
resection for a non-neoplastic disease. Each patient gave a written
informed consent in accordance with Italian law. The study
project was submitted and approved by the Ethic Committee of
AOU of Second University of Naples, Italy.
Clinical Data and Tumour Specimen Acquisition for
immunohistochemistry
70 patients (see Table 2) were treated at the Second University
of Naples and at Regina Elena Cancer Institute, between 2001
and 2006. Clinical data were obtained by retrospective chart
review. Survival period was determined from the date of initial
surgery. Indeed, surgery/biopsy was the first step of diagnosis in all
patients. As a consequence surgery/biopsy and diagnosis were
overlapped. Follow-up was available for all patients. Four subjects
who died of causes other than MM during the follow-up period
were excluded from the study. 44 patients were treated with
cytoreductive surgery, while all patients were treated with
radiotherapy or chemotherapy. The same staging procedures
were used for all the patients. Tissues from 70 MM specimens (45
epithelioid, 11 sarcomatoid and 14 mixed mesotheliomas)
obtained from open biopsies or pleurectomies were collected and
fixed in 10% formalin before being embedded in paraffin. The
formalin-fixed, paraffin-embedded samples were sectioned at
5 mm and stained with hematoxylin and eosin. The histological
diagnosis was reexamined by two pathologists (A. B. and P.M.)
according to the WHO. In some cases, immunohistochemical tests
were included for verification of the diagnosis as described [18]. In
addition, the most representative blocks were selected to be cut
into new 5 mm-thick sections for immunohistochemical studies.
Each patient gave a written informed consent in accordance with
Italian law. The study project was submitted and approved by the
Ethic Committee of AOU of Second University of Naples, Italy
and of Regina Elena Cancer Institute.
Table 1. Clinical characteristics of patients enrolled for the
microarray analysis.
Patient Age Sex Histological subtype
1 69 Male Epithelioid subtype
2 59 Male Biphasic subtype
3 61 Male Epithelioid subtype
4 59 Male Biphasic subtype
5 59 Male Biphasic subtype
6 78 Male Biphasic subtype
7 70 Female Epithelioid subtype
8 71 Male Epithelioid subtype
9 55 Male Biphasic subtype
doi:10.1371/journal.pone.0007016.t001
MMP14 in Mesothelioma
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Sections from each specimen were cut at 5 mm, mounted on
glass and dried overnight at 37uC. All sections were then
deparaffinized in xylene, rehydrated through a graded alcohol
series and washed in phosphate-buffered saline (PBS). PBS was
used for all subsequent washes and for antibody dilution.
Endogenous peroxidase activity was blocked by 5% hydrogen
peroxide. For immunohistochemistry, tissue sections were heated
twice in a microwave oven for 5 min each at 700 W in citrate
buffer (pH 6.0) and then processed with the standard streptavidin-
biotin-immunoperoxidase method (DAKO Universal Kit, DAKO
Corp., Carpinteria, CA, USA). Rabbit polyclonal anti-MMP14
(Affinity BioReagents, Golden, CO, USA) was used following the
manufacturer’s indications (working dilution 1:200). Diaminoben-
zidine was used as the final chromogen, and hematoxylin as the
nuclear counterstain. Positive controls included in each experi-
ment consisted of tissue previously shown to express the antigen of
interest. All samples were processed in the same run as one batch.
Two observers (A.B. and P.M.), blinded to treatment conditions,
evaluated the staining pattern of the proteins separately and
quantized the protein expression in each specimen by scanning the
entire section and estimating the number of positive cells at the
high-power-field 10620 and described as: low (from 1% to 20% of
positive cells); medium (from 21% to 40% of positive cells); and
high (more than 40% of positive cells). The level of concordance
for the final scores, expressed as the percentage of agreement
between the observers, was 92.5% (37 over 40 cases). In the
remaining three specimens, the score was obtained after collegial
revision and agreement. An univariate survival analysis for each
prognostic variable on overall survival was estimated according to
the Kaplan-Meier method [19]. The terminal event was death
attributable to cancer. The statistical significance of the differences
in survival distribution among the prognostic groups was evaluated
by the log-rank test [20]. p values ,0.05 was regarded as statistical
significant in two tailed tests. SPSS software (version 10.00, SPSS,
Chicago) was used for statistical analysis.
GeneChip array sample preparation
Total RNA was extracted from each of the tumour and control
samples using the RNeasy Mini kit (Qiagen, Valencia, CA).
Biotinylated cRNA target was produced starting from 3 mg of total
RNA in according to Affymetrix (Santa Clara, CA) instructions
and for each sample 15 mg were fragmented to a length of 20–
200 bp before hybridization to Genechip HGU133 plus2.0 arrays.
All the hybridization, washing, staining and scanner procedures
were done using a Genechip Affymetrix station (Fluidics station
450, GeneChip Scanner 3000) as recommended by manufacturer.
Laser scansion generated digitized image data files and CEL file
that were used for the subsequent statistical analysis.
GeneChip array data analysis
Microarray quality control and statistical validation were
performed using Bioconductor [21]. The presence of hybridiza-
tion/construction artifacts was evaluated with the fitPLM function
(Bioconductor package affyPLM). The probe (PM) intensity
distribution was evaluated using hist function (Bioconductor
package affy). Probe set intensities were obtained by means of
GCRMA [22] and normalization was done according to quantiles
method [23]. The number of genes evaluated was reduced by
applying an interquartile (IQR) filter (24953 probe sets with IQR
$0.25 were retained) followed by an intensity filter (17716 probe
sets with expression signal $100 in at least 25% of the arrays were
retained) to remove the non significant probe sets (i.e. those not
expressed and those not changing) [24]. Differential gene
expression between MM and wild-type samples was detected
using an empirical Bayes method [25] together with a false
discovery rate (FDR) correction of the P-value [26]. Specifically,
470 probe sets (386 genes) were selected using a corrected p-value
threshold of 0.05 and fold change threshold of |log2(fc)| $1.
OneChannelGUI graphical interface package was used to run any
of the described analysis [27]. Ingenuity Pathway Analysis
(Ingenuity Systems, http://www.ingenuity.com/) was used to
functionally annotate genes according to biological processes and
canonical pathways and to search for potential biomarkers.
Hierarchical clustering analysis of the biomarkers expression data
was done using Tmev (http://www.tm4.org/mev.html).
Microarray data reported in the manuscript was described in
accordance with MIAME guidelines. Microarray data were deposited
on GEO database (http://www.ncbi.nlm.nih.gov/projects/geo/) as
GSE12345 series.
Quantitative Real-Time PCR analysis
Total RNA(2 mg)fromnormaland tumoursampleswasconverted
to cDNA using High- Capacity cDNA Reverse transcription kit
(Applied Biosystem) under conditions described by the supplier.
cDNA from this reaction was used directly in the qRT-PCR analysis.
Gene specific primers for the selected genes (MMP14: Forward 59
TCAAGGAGCGCTGGTTCTG, Reverse 59 AGGGACGCCT-
CATCAAACAC; TOP2A: Forward 59 TGCCAATGCTTCCAA-
GTTACAA, Reverse 59TGTATGTCTGGGTCCATGTTCTG;
MDK: Forward 59 CAAAGGCCAAAGCCAAGAAA, Reverse 59
GATTAAAGCTAACGAGCAGACAGAAG; AURKA: Forward 59
CACCTTCGGCATCCTAATATTCTT, Reverse 59GGGCATT-
Table 2. Characteristics of the patients enrolled in the study.
Median age (range) 65 (45–81) years
Gender (female vs male) 29 vs 41
Surgery
Yes 44 (64%)
No 26 (36%)
T status
T1 4 (6%)
T2 13 (19%)
T3 23 (33%)
T4 4 (6%)
TX 26 (36%)
N status
N0 27 (39%)
N1 3 (4%)
N2 14 (21%)
NX 26 (36%)
Histology
Epithelioid 45 (64%)
Mixed 14 (21%)
Sarcomatoid 11 (15%)
MMP-14 score
Low 19 (27%)
Medium 32 (46%)
High 19 (27%)
doi:10.1371/journal.pone.0007016.t002
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AAAGGAAAAC,Reverse59GAGGCTTTGCTCTGATTTCGA;
EDG1: Forward 59 GAGCGAGGCTGCGGTTT Reverse 59GGT-
GGTTCGATGAGTGATCCA) were designed using Primer Ex-
press 2.0 software (Applied Biosystems, Foster City, CA) and, when
possible, the same coding target region identified by the Affymetrix
probe was amplified; otherwise, primers were designed on the coding
sequence. The specificity of each target amplicon was assessed by
dissociation curve analysis and all amplicons were spanning over
exon-exon regions to avoid genomic amplification. Quantitative
PCRs were done on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems) in 96-well plates using a final volume of
20 mL and the following cycle conditions: 50uCf o r2m i n u t e s ,9 5 uC
for 10 minutes, and then 40 cycles of 15 seconds at 95uCa n d1
minute at 60uC. All quantitative PCR mixtures contained 1 mL
cDNAtemplate(correspondingto20 ngretrotranscribed totalRNA),
1x Sybr Green PCR-Master-Mix (2x; Applied Biosystems) and
150 mmol/L of each target-specific primer. For each experiment, a
no-template reaction was included as negative control. The
expression of each target gene was evaluated by a relative
quantification approach [28], using Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH: Forward 59 GGAGTCAACGGATTT-
GGTCGTA, Reverse 59 GAATTTGCCATGGGTGGAAT) as
internal reference. Internal control was selected within not
differentially expressed genes in this experiment. The Ct values of
triplicate RT-PCR reactions were averaged for each gene in each
cDNA sample. For each sample assayed, the level of gene expression
for the corresponding gene of interest was calculated against that of
the reference gene (GAPDH). Control sample were used as calibrator
and each target genes was accepted as differential expressed when the
DDCt absolute value was .1, which correspond a 2-fold change in
transcript abundance. The standard deviation was calculated for
samples within each tissue group.
Results
Clinical Characteristics of Patients enrolled for microarray
analysis and Gene expression profile
Nine patients with MM underwent surgical resection and debulking
for pleural MM. Their clinical characteristics are shown in Table 1.
The average age at time of operation was 64.5 years. The average
smoking history was 30.3 pack-years. Seven patients had some history
of asbestos exposure. Six patients underwent a pleurectomy. Pathology
was either epithelioid (45%), or biphasic (55%).
We performed a genome wide transcription profiling to identify
prognostic early molecular marker. Specifically, we compared
9 MM versus 4 normal donors pleura (see materials and methods).
Transcription profiling was performed using HG U133 plus 2.0
GeneChips and data were analyzed using the oneChannelGUI
Bioconductor package [27]. Principal Component Analysis (PCA)
(Figure 1) clearly indicates the presence of a certain amount of
differences between mesothelioma and normal pleura since they
group into two distinct clusters, separating tumour from control samples.
The PCA results showed a molecular homogeneity shared by tumour samples,
and prompted us to proceed in the subsequent statistical analysis without
discriminating between epithelioid and biphasic subclasses. The discrepancy
between transcription data and histological classification is due to the fact that
MM histology shows an important phenotypic variability and the classification
is based on the relative amount of epithelial and spindle cells and can therefore
can be very dependent on the pathologist that performs the analysis.
The complexity of the data set was reduced removing the non
significant probe sets (i.e. those not expressed and those not
changing). This filtering procedure reduced the initial set of 54675
probe sets to 17716 that were used for further analysis.A moderated
t-test [25] was used to detect differential expression between tumour
and normal tissues. Specifically, 386 genes (470 probe sets) were
selected using a BH corrected p-value #0.05 and |log2(fc)| $1.
Validation of selected gene expression
To independently test the validity of the differential expression
signatures determined by microarray analysis, we measured the
expression patterns of some of the putative biomarkers. We assessed
gene expression of 6 representative genes in all tissue samples using
quantitative real-time polymerase chain reaction (qRT-PCR). In all
cases, the qRT-PCR results of the analyses confirmed the
differences detected in our microarray analysis (Table 3).
Analysis of specific pathways and genes
Functional pathway analysis of the differentially expressed genes
was performed using ‘‘Ingenuity Pathways Analysis’’ (IPA, http://
www.Ingenuity.com) a web-delivered application that enables to
discover and analyze functional relation between differentially
expressed genes. For each probe set, IPA generates a metadata file
containing information on how to map the given dataset onto
molecules associated with specific disease, cellular functions and
Figure 1. PCA of the full datasets for normal and tumour
samples. PCA shows homogeneity of the experimental group, coupling
the normal (red) and tumour (blue) samples in two distinct clusters.
doi:10.1371/journal.pone.0007016.g001
Table 3. qRT-PCR validation of microarray results.
fold change
Gene arrays q-RT-PCR
MMP14 6.189952 5.012825
TOP2A 5.568903 3.597234
MDK 3.595405 4.189205
AURKA 3.564461 2.00000
TGFBR3 23.74758 23.0022
EDG1 22.02870 21.26722
doi:10.1371/journal.pone.0007016.t003
MMP14 in Mesothelioma
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7016canonical pathways; thus, it is possible to obtain indications on the
cellular processes involved in the disease. IPA analysis was
performed analyzing a file containing the global gene list, obtained
from filtering procedures (17883 probe set), that includes statistical
validated genes (470 probe sets, 386 genes). A complete list of the
386 genes differentially expressed in tumour samples is found in
Table S1. This analysis highlighted that cell cycle, cellular
proliferation, DNA damage and cancer are the most consistent
functional classes found enriched within the set of differentially
expressed genes (Figure 2). The complete gene list of the most
relevant networks is reported in Table S2.
Condensin Complex and kinesin family
Among genes related to DNA replication, in our data set we
found as up-regulated components of the condensin complex (e.g.
BRRN1, CNAP1, NCAPD3) and members of the kinesin family
(e.g. KIF14, KIF23, KIFC1). These genes have not been previously
described in MM. The two condensin complexes (I and II) play an
essential role in mitoticchromosome assembly and segregation. The
complexes make distinct contributions to metaphase chromosome
architecture defects [29,30] and they are essential to cell division
because their knockdown generates mitotic spindle defects [31].
Thus, condensin over-expression could contribute to genome
instability. The kinesin family groups microtubule-based motor
proteins that play important role in multiple cellular processes
includingintracellulartransportandcelldivision.Recently,elevated
kinesins expression was found in cancer and associated with poor-
prognosis [32]. Data in vitro seems to confirm their role in cancer,
since their knockdown can decrease tumourigenicity [33]. Further-
more, this family is a substrate for AURKA, that we found over-
expressed in our experimental setting (see later), and whose over-
expression has been correlated with chromosomal instability and
clinically aggressive disease [34].
Cancer and cell-death network
Among the up-regulated genes associated to the cancer and cell
death-related network (2), we found molecules with known
function in cancer progression, such as the protein kinase
CDC2, that has a crucial role in cell cycle control and in cell
cycle progression, and whose over-expression has been reported in
MM [16]. CHEK1, instead, is a checkpoint kinase involved in
DNA damage response, whose depletion leads to metaphase block
[35]; its role, in MM, if any, is unknown. Other genes associated to
other cancers (e.g. BUB1 in bladder, MAD2L1 in breast) [36,37]
are involved in spindle checkpoint.
We found up-regulated the maternal embryonic leucine zipper
kinase (MELK), a gene associated to unfavorable survival in MM
[17] and known to be associated both to MM and other cancers.
MELK increased expression seems to be restricted to cancer tissue
[38,39] while its silencing causes a block of tumour cells
proliferation: a result that permits to hypothesize for MELK a
role as molecular therapeutic target [39].
Consistent with previously published results, we found up-
regulated some genes associated to poor survival and included in
different prognostic classifiers, such as BTG2 (Karmanos gene
classifier and MSKCC gene classifier) [13,17], BIRC5 and KIF4A
(Karmanos gene classifier), or SEPT9 (Brigham list) [15].
Furthermore, we found WT1, a gene described as favorable for
survival in MSKCC gene classifier, down-regulated in our list.
Cell cycle regulation
Among the up-regulated genes, not previously associated to MM,
we found several cyclin genes (e.g. CCNA2, CCNB1, CCNB2,
CCNL2). CCN gene family contributes to cell cycle regulation.
Cyclin dependent protein kinases (CDKs) regulate cell cycle
transitions and are essential for cellular integrity. In fact, they play
pivotal role, ranging from DNA damage and spindle assembly
checkpoints - before entering mitosis - to kinetochore and centrosome
maturation and separation, in regulating the timing of entrance and
exit of mitosis [40]. Up-regulation of these mitotic kinases was not
surprising, because it is well known their involvement in tumourigen-
esis,considering also the central role of the phosphorylation in mitotic
checkpoints, spindle function, and chromosome segregation.
CCNA2 (Cyclin A/Cdk2) plays an important role during both
G1/S and G2/M eukaryotic cell cycle transitions, activating
CDC2 or CDK2 kinases. CCNA2 over-expression is frequently
detected in many tumours [41] and it has been associated with
poor prognosis in different cancers.
CCNB1, another key component in cell cycle control, has a role
in G2/M progression, acting with CDK1 to control chromosome
condensation [42]; it has been implicated in tumourigenesis and in
metastasis in different cancers [43].
CCNB2 is involved in chromosomal instability and its over-
expression modifies spindle checkpoint and chromosome segrega-
tion [44].
These cyclins, that were not previously associated to MM, are
related to each other in the regulation of centrosome separation
and in the nuclear-envelope breakdown, even if they have different
roles. CCNA2 is involved in mitotic entry or completion because it
is the only required for a correct timing of centrosome separation
and nuclear-envelope breakdown, while CCNB1 and CCNB2
have a role in mitotic progression in a CCNA2-dependent manner
[45]. Thus, their concomitant over-expression could have a role in
the mesothelioma tumour progression and maintenance.
Spindle checkpoint and cell cycle progression
The network (2) also contains genes involved in spindle
checkpoint function and in cell cycle progression - two processes
involved in cancer development - as Aurora Kinase-A (AURKA),
a well known cell cycle regulated kinase, highly expressed both in
various cancer cells and during mitosis, whose role in MM is well
Figure 2. Top enriched Biofunctions as determined by
Ingenuity analysis. The top five biological functions found enriched
in the set of transcripts modulated in tumour mesothelioma samples
detected by Ingenuity.
doi:10.1371/journal.pone.0007016.g002
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because it seems directly correlated to survival and it is frequently
over-expressed in many tumours [46,47,48].
Remarkably, we found over-expressed DLG7, a gene recently
described as a potential oncogenic target of AURKA. DLG7 is an
essential component of the mitotic apparatus required for spindle
microtubules organization in a complex dependending on AURKA
activity, that regulates DLG7 as a downstream target [49]. DLG7
was first identified as a potential oncogene, over-expressed in
human hepatocellular carcinoma (HURP hepatoma up-regulated
protein) [50], having an expression profile well correlated to
AURKA. This suggests that they may be coordinately regulated
through stabilization of DLG7 by AURKA [51]. DLG7 protein
binds microtubules affecting their organization and is required for
chromosome congression and alignment, functions essential for
bipolar spindle formation. DLG7 over-expression in HeLa cells
results in hyperstabilization of the mitotic spindle that could
promote aneuploidy and genomic instability by generating subtle
defects in chromosome congression [52]. Thus, over-expression of
DLG7 and AURKA in cancers and in MM suggests that mis-
regulation of this complex could play a role in carcinogenesis.
FOXO3A pathway
Among down-regulated genes it is worthy to note FOXO3A, a
member of the forkhead transcription factors family that acts as a
trigger for apoptosis, targeting multiple genes involved in tumour
suppression [53]. It is known that RAS–ERK is an essential
oncogenic signaling cascade that promotes tumour cell growth and
development. A recent study demonstrated that down-regulation
of FOXO3A promotes tumourigenesis and that this process
involves a direct interaction of FOXO3A with oncogenic kinases,
such as AKT and ERK that negatively regulate it [54].
Accordingly with this observation, we found over-expressed
EPHB2 and MDK. EPHB2 is a tyrosine kinase receptor that
regulates ERK and plays an important role in oncogenic processes
being involved in a wide range of processes directly related with
tumourigenesis and metastasis [55]. MDK is a growth factor
associated with cancer development, often related to drug-
resistance, that increases AKT proteins activation [56]. Looking
for the functional relationship among these genes, we tried to
connect them using IPA and interestingly found connections that
well fit with fold change value and that finally result in FOXO3A
inhibition (Figure 3).
Mesothelioma biomarker identification
As previously described, MM is a rare but highly lethal tumour
that develops after long time latency from the first asbestos
exposure. Unfortunately, MM is diagnosed when the tumour has
occurred and there are no more effective treatments to use. The
epidemic of MM is increasing in countries that have made vast use
of asbestos in the past. The epidemic curve follows that of asbestos
consumption over time and the plateau is expected to be reached
in the period 2010–2020 [12]. For this reason, the identification of
early tumour biomarkers suitable for an early diagnosis and a
proper prognosis becomes a priority for MM treatment.
In order to identify genes to use as potential early diagnostic
and/or prognostic biomarkers, we used our dataset as starting
template to perform an IPA-biomarker analysis. IPA is a tool
capable of retrieve candidate biomarkers implicated in disease
processes: it determines if they could be detected in body fluids.
From this analysis we obtained a gene list containing 100 putative
biomarkers (1). To assess a relationship between differential
expression in tumour samples and putative mesothelioma
biomarker genes, we performed a hierarchical aglomerative
clustering of the expression of the 100 putative biomarkers, using
the TMEV tool [57] (Figure 4).
Among the down-regulated transcripts in the tumour samples,
34 were found eligible for Ingenuity analysis. The analysis
highlighted the presence of a set of transcripts associated to
cellular movement, molecular transport and immune response.
Among the transcripts up-regulated in the tumour samples, 54
were found eligible for Ingenuity function and pathway analysis.
These transcripts were associated mainly to cancer and cell cycle.
We analyzed genes in more detail, looking for potential
biomarkers that could be specific for MM. To this end, we
restricted our analysis first to molecules linked both to cancer and
respiratory disease and then to proteins potentially detectable in
specific body fluids such as blood or plasma. Moreover, to
investigate biological pathways affected by the predictive bio-
marker genes and to better select genes potentially usable as
diagnostic marker, we built a functional pathway to search direct
interactions. The retrieved interaction pathway (Figure 5) affects
genes, involved in cell cycle regulation, that have increased
expression in tumour samples.
As is shown in Figure 5, the detected interactions regard only
few, but interesting, genes with decreased expression in tumour.
Among them we found EDG1 and SYNPO2. EDG1 is a G
protein-coupled receptor involved in cell-cell adhesion, reported as
a novel antiproliferative protein, whose inhibition increases breast
cancer cell growth [58]; SYNPO2, has been recently characterized
as a tumour suppressor gene that inhibits cancer growth and
metastasis both in vitro and in animal models [59].
Matching together the biomarker molecules and genes included
in the pathway, we observed some interesting genes that could be
further investigated as putative biomarkers. In particular, since
secretory or membrane proteins might be especially useful for
diagnostic aims and, possibly for therapeutic purposes, we focused
our attention on MMP14 (MT1-MMP), LAMA5 and LAMC2.
Figure 3. FOXO3A functional relationship. Functional pathway
between genes acting on FOXO3A built by Ingenuity; the relationships
are in agreement with the observed gene expressions; arrows indicate
the direction and the relation type.
doi:10.1371/journal.pone.0007016.g003
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protein family, involved in the breakdown of extra-cellular matrix
that has been associated with many different tumours. MMPs have
a fundamental role in basement-membrane penetration during
metastasis as well as in highly aggressive tumours or in late stages
[60]. They can promote tumour progression through different
signalling functions including apoptosis, angiogenesis and immu-
nity. Their broad functions candidate them as drug targets [61].
The MMP family in mammals includes different protein and peptide
hydrolase that share a common domain structure. Among the member so far
identified ‘‘MMP’’ include the membrane-type proteins that are produced as
zymogen (pro-MMP), while ‘‘MT1– MMPs’’ include members with a
membrane anchor, a feature for which they are thought to play a role in
pericellular proteolysis. Overexpression of specific MMPs, as the gelatinases A
(MMP-2) and B (MMP-9) and stromelysin-3 (MMP-11), have been
widely associated to tumour progression and metastasis in different tumours.
Furthermore MMP-2 and -9 expression has been described in MM cell lines
[62].
MMP activity is regulated by TIMPs (tissue inhibitors of
metalloproteinases), which are their endogenous inhibitors. The
balance between MMPs/TIMPs regulates the extracellular matrix
(ECM) turnover and remodeling during normal development and
pathogenesis.
The MMPs zymogen activation is strictly controlled by a membrane-
associated event. The process strictly connects MT-MMP and MMP
functions, and it has been shown that MMP14 is essential for proMMP-2
activation: pro-MMP-2 activation by MMP14/TIMP complex is realized
in an environment of low TIMP concentration; furthermore TIMP 4 over-
expression can reduce tumour invasiveness [63].
Taking in account that TIMPs role in tumour invasion and
metastasis is achieved through MMPs inhibition, these proteins
could be a new group of therapeutics for MMPs specific inhibition
and could represent a new approach in cancer therapy [64].
According with previous published data, reporting an imbalance
between matrix metalloproteinases and their inhibitors [65,66], in
our data set we found an opposite expression of a MMP (MMP14
up-regulated) and of a TIPM (TIPM4 down-regulated).
MMP14 reveals to be a very intriguing molecule that seems to
be important in tumour progression by promoting cell invasion
and matrix degradation. Furthermore, MMP14 has been
identified as a key player during angiogenic response, a process
regulated by VEGF [67] that we also found up-regulated. MMP14
shows a relationship with LAMA5 and LAMC2 (Figure 5) and this
is in agreement with our analyzed phenotype. It is reported that
MMP14 cleaves the LAMC2 gamma -2 chain, producing a
fragment release usually increased in cancer cells. This process
could be the way in which MMP14 promotes cell migration and
invasion [68]. Furthermore, this proteolytic cleavage is known to
convert laminin properties from cell adhesion to motility type,
being a distinctive trait of invasive cancer cells.
We investigate the presence of MMP14 up-regulation in tumours using
Oncomine (http://www.oncomine.org/) and GEO (http://www.ncbi.nlm.
nih.gov/geo/).
In Oncomine database there are several cancer studies in which MMP14
was found up-regulated such as ovarian, breast and colon but no MM data sets
have been recorded.
GEO database records about three hundred gene expression cancer profiling
studies in which MMP14 results to be up-regulated and frequently related to
cancer progression. Looking for over-expression of this gene in MM, two studies
are available, one performed in mesothelial cell lines (GDS2604 series), [69]
and the other performed on MM tumor samples (GDS1220 series), [16].O n
the basis of GEO data, MMP14 was found up-regulated in the tumour
samples, but it was not discussed in the papers associated to the datasets.
In order to better define the possible prognostic value of MMP14
expression in MM, we decided to investigate MMP14 expression by
immunohistochemistry in a group of well-characterized MM
specimens. Table 2 shows the characteristics of the patients enrolled
in this study and a summary of the results from immunohistochem-
ical analysis. MMP14 was always expressed in MM, but with
different expression levels; staining was always cytoplasmatic.
Figure 6 shows some typical immunohistochemical staining for
MMP14. By univariate analysis overall survival was influenced by T
and N status, and by histology, being the sarcomatoid pattern
mostly related to a worse prognosis. Interestingly, survival was also
influenced by MMP14 expression (p,0.0001). The median survival
in patients with low MMP14 expression was clearly longer than in
those patients with high MMP14 expression (24 months vs 5
months).Ontheotherhand,cytoreductive surgerydidnotinfluence
the overall survival in our patients’ population (Table 4). In Figure 7
is depicted a Kaplan-Meier survival plot for all patients showing a
Figure 4. Clustering of biomarker gene list. Hierachical agglom-
erative clustering of the 100 transcripts found differentially expressed in
tumour samples and associated to biomarkers by Ingenuity.
doi:10.1371/journal.pone.0007016.g004
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and poor outcome. Chemotherapy and radiotherapy did not show
any impact on overall survival in univariate analysis (data not
shown). Indeed, by a multivariate Cox regression analysis, the only
parameter that resulted to influence overall survival was MMP14.
The calculated relative risk of death in MM patients with low
MMP14 expression was significantly lower than patients with high
MMp14 expression (P=0.002). All other parameters significantly
associated withprognosis in univariate analysis did not influence the
overall survival when evaluated by multivariate analysis, except for
the T status (P=0.01), while the histological pattern reached only a
borderline significance (p=0.079) (Table 5).
Discussion
MM is a highly aggressive neoplasm correlated to asbestos
exposure and current therapies are mainly based on clinical stage
and tumour histology. Even if favorable prognostic factors mostly
derive from the mixed and epithelioid histology, precise identification
of predictive factors or prognostic markers actually needs to be based
Figure 5. Gene network of deregulated genes associated to cell cycle and selected as putative biomarkers as determined by
Ingenutity. Genes are positioned in subcellular layout. Genes in red showed increased expression in tumour samples while genes in green
decreased their expression in tumour. Up-regulation of some cyclin genes is in agreement with the tumour higher proliferation rate. Relationships are
marked by arrows: dashed line arrows mark indirect interactions, filled line arrows mark direct interactions.
doi:10.1371/journal.pone.0007016.g005
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prolongs the survival of few months and the cytoreductive therapy
followed by chemotherapy/radiation combined treatment has been
shown to improve survival only in early MM patients [5]. For these
reasons, the identification of molecular early diagnostic or prognostic
marker becomes fundamental in order to apply therapeutic protocols
in the right time. Concerning these aspects, gene expression profiling
of MM is a challenge promise, not only to identify prognostic
indicators of clinical outcome, but as a means of characterizing
specific molecular abnormalities that may underlie all the time-
related poor signs of MM. The gene expression analyses have been successfully
used to classify tumours in groups that correlate either with tumour differentiation
degree or with patient survival with more accuracy [70].
Molecular signature of MM represents the only way to identify predictive
factors or prognostic molecular markers in order to identify in advance (in pre-
surgery phase) suitable long-term survivors. Furthermore the outcome prediction
in MM, based only on histological classification, has been revealed to be error
prone and ineffective for patients [71]. MMs show a phenotypic variability
and are classified based on to the relative amount of epithelial and spindle cells.
Indeed the histological heterogeneity of MM samples might correspond to the
same expression profile, thus gene expression analysis could extend and refine
the standard pathologic analysis.
Our exhaustive analysis of gene expression in MM, compared to
normal pleural samples, confirm the complexity of biologic events
responsible of neoplastic transformation. Indeed, our data depict a
complex scenario, where genes involved in different important
functions for the cells (such as cellular assembly and organization, cell
cycle regulation, apoptosis, cellular movement and DNA repair) are
simultaneously involved to produce tumour phenotype. Therefore,
this study confirms the aptitude of microarray technology in defining
molecular pathways involved in MM pathogenesis and progression.
In addition, our results corroborated previously observed expression
patterns of a series of genes [13,15,17], and revealed new genes
differentially expressed during MM progression.
Our data - according to recent studies performed in MM using microarray
technologies - reported deregulation of different genes involved in mitotic
checkpoint that might have a key role in MM development and maintenance.
Our list contains several genes previously described as prognostic classifier.
Furthermore, we described novel genes, never associated before to MM, possibly
involved in tumour progression.
Among genes related to DNA replication, we identified as up-regulated
components of the condensin complex and members of the kinesin family (e.g.
BRRN1, CNAP1, NCAPD3, KIF14, KIF23, KIFC1). The condensin complex
is essential to normal cell division [30] and its over-expression probably contributes
to genome instability. The kinesin family groups microtubule-based motor proteins
that play important role in multiple cellular processes, including intracellular
transport and cell division. Data in vitro seems to confirm their role in cancer [33].
Kinesins and condensins are substra t ef o rA U R K A ,ag e n ew h o s eo v e r -
expression in MM has been correlated with an aggressive course [17].
Figure 6. Immunohistochemical staining of MMP14 in human pleural mesotheliomas. A: Strong cytoplasmic expression (original
magnification6200); B: Low cytoplasmic expression (original magnification6200); C: Negative control (original magnification6200); D: Low to
undectable expression (original magnification6200).
doi:10.1371/journal.pone.0007016.g006
Table 4. Correlation with survival in univariate analysis of the
anatomo-clinical and immunohistochemical parameters
selected for the mesothelioma patients.
Median Survival
Time (months)
95% C.I.
(months) P value
MMP14 score ,0.0001
Low 26 21.15–26.84
Medium 14 9.84–18.15
High 5 3.68–6.32
T stage 0.001
1 Not reached -
2 21.0 12.40–29.56
3 11.6 2.49–17.50
4 10.0 3.41–15.60
N stage 0.020
0 17.0 7.59–26.41
1 23.0 9.20–27.34
2 10.0 6.88–12.87
Surgery 0.398
No 14.0 10.76–17.24
Yes 16.0 11.73–20.27
Histology 0.005
Epithelioid 16.0 13.05–18.95
Mixed 11.0 9.18–12.81
Sarcomatoid 6.0 3.57–8.42
doi:10.1371/journal.pone.0007016.t004
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regulates different cell cycle events, supporting centrosomes maturation and
spindle assembly and stability; its over-expression was associated in MM
with chromosomal instability and clinically aggressive disease [17].
Furthermore, we found over-expressed DLG7 another essential component
of the mitotic apparatus, recently described as a potential oncogenic target of
AURKA. It is worthy to note that the anti-tumour effects obtained from the
first generation of Aurora kinase inhibitors [72] might be tested also in MM
treatment.
We found up-regulated several cyclin genes, that play role both in G1/S and
in G2/M eukaryotic cell cycle transitions, as CCNA2, CCNB1, CCNB2,
CCNL2. Cyclin A/Cdk2 (CCNA2) and CCNB1 are present in many
tumours [41] and some were previously associated with poor prognosis and in
metastasis [43,73]. Together these cyclins have different roles in centrosome
separation regulation or in nuclear-envelope breakdown, but their concomitant
over-expression might have a role in MM progression and maintenance. Other
molecules up-regulated with a well-known function in cancer progression, are
CDC2, a protein kinase that has a crucial role in cell cycle control and in cell
cycle progression [74,75] and CHEK1, a checkpoint kinase involved in DNA
damage response, whose depletion leads to metaphase block [35].
Our data confirm the association between MELK and MM. Up-regulation
of this gene has been related to unfavorable survival in MM [17].
Finally, in agreement with previously published results, we found up-
regulated genes associated to poor survival and included in different prognostic
classifiers, such as BTG2 (Karmanos gene classifier and MSKCC gene
classifier) [13,17], BIRC5 and KIF4A (Karmanos gene classifier), SEPT9
(Brigham list) [15], and down-regulated WT1, a gene described as favorable
for survival in MSKCC gene classifier.
The transcriptome analyses reported above, identified as up-
regulated in MM almost all genes related to cellular processes
whose deregulation might play a crucial role in cancer
development and progression.
Figure 7. Kaplan-Meier survival plot for MMP14. The MM patients with high MMP14 expression have a significant shorter survival time respect
to the low MMP14 expressors.
doi:10.1371/journal.pone.0007016.g007
Table 5. Prognosis of mesothelioma expressed as hazard
ratios (HR) and 95% confidence intervals (CI) associated with
selected immunohistochemical and anatomo-clinical
parameters.
HR value 95% C.I. P value
MMP14 0.002
Low 1 -
Medium 1.56 1.03–2.34
High 3.56 2.48–5.90
T stage 0.011
11 -
2 1.23 0.56–1.44
3 2.55 1.11–2.98
4 2.76 2.53–3.52
N stage 0.212
01 -
1 0.79 0.59–1.63
2 1.95 1.07–2.38
Histology 0.079
Epithelioid 1 -
Mixed 0.67 0.48–1.07
Sarcomatoid 0.49 0.32–0.87
Cox regression analysis was performed (adjusted for all the other variables) for
the following factors: MMP14, T stage, N stage, Histology
doi:10.1371/journal.pone.0007016.t005
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these data must be considered not conclusive; nevertheless, the
information acquired could indicate some of the molecular
pathways involved in MM pathology. Indeed, the role of these
newly identified genes is being evaluated in further studies, aimed
to analyze the protein expression pattern and the protein function
in vitro and in vivo in MM cells.
In the second part of our manuscript, we focused our attention
on the definition of putative biomarkers for early diagnosis and
prognosis in MM. Among genes involved in mesothelial cells
tumour transformation we directed our attention to molecules
present in the extra-cellular space and detectable in biofluids such
as blood. These new molecules could be potentially used as early
diagnostic MM markers to screen individuals previously exposed
to asbestos. To this aim we focused our attention on MMP14. To
the best of our knowledge, this is the first paper investigating
MMP14 in MM. We found MMP14 to be widely expressed in all
the samples analyzed, even if with different expression levels.
Interestingly, high immunohistochemical expression of MMP14
was significantly correlated with poor survival. These observations
strongly suggest that MMP14 plays a role in tumour progression in
MM and could be a target for MM biological therapy. In
particular, MMP14 could represent a putative target for a therapy
based on specific MMP14 inhibitors. To consider MMP14 as drug
target, detailed analysis of its inhibition effects in patients are
needed. Treatment with MMP14 inhibitors is currently under
investigation and preliminary experiments have been performed
on Mmp14-null mice [76], that showed multiple severe side effects
probably related to secondary development defects and not to the
protein deficiency. Thus, in order to consider MMP14 as anti-
target, a more detailed MMP14 inhibition analysis in adults mice
and in patients is needed. To this aim, high throughput proteomic
techniques were recently applied to analyze in detail the effects on
cells of a MMP14 inhibitor drug, in order to predict and possibly
avoid side-effects of drug treatment in patients [77]. Further
studies are urgently required both at molecular and clinical level to
confirm these observations and to eventually propose MMP14 as a
concrete target for therapy. Finally, in order to determine if the
amount of cytoplasmic MMP14 reflects the amount that is
secreted, it would be necessary to carry out prospective studies,
analyzing the amount of MMP14 in the extra-cellular space of
MM patients. These studies are necessary in order to eventually
consider MMP-14 a biomarker for MM.
Conclusion
MM is a rare, highly aggressive tumour related to asbestos
exposure that develops after long time latency, with a very short
survival after diagnosis. Since cancer therapies are more effective if
used in the initial stages we analyzed MM to identify early
biomarker that could be used to diagnose it in advance. Using
microarray technology, we analyzed MM and normal pleural
samples identifying new genes involved in tumour progression,
focusing our attention on the identification of putative biomarkers
for early diagnosis and prognosis in MM. To this aim we analyzed
the differentially expressed genes, looking for potential biomarkers
specific for MM by identification of molecules both linked to
cancer and respiratory disease, and also potentially detectable in
specific body fluids such as blood or plasma.
We directed our attention to molecules present in the extra-
cellular space, because these molecules could be used as early
diagnostic MM markers to screen individuals previously exposed
to asbestos. In particular, we found MMP-14 a member of the
metalloproteinase family that mediates homeostasis of the extra-
cellular environment. The protein mediates the breakdown of
extra-cellular matrix a process needed for basement-membrane
penetration during metastasis and its over-expression has been
associated with many different tumours.
We found that expression of MMP-14 has a prognostic value in
a group of MM patients showing that high immunohistochemical
expression of MMP14 was significantly correlated with poor
survival.
A prospective trial is undergoing in order to confirm the prognostic value of
MMP-14 expression in MM patients. Finally, to better determine the role of
MMP-14 as MM biomarker, our research group is actually working on the
identification of MMP14 in the blood of MM patients. Our preliminary data
show that this protein is, indeed, detectable in the peripheral blood of several
MM patients, while it is not revealed in healthy controls (data not shown).
Molecular analyses of MM are becoming crucial for the tumour comprehension
next step that is the identification of molecules that can be used not only for
prognostic purposes but to diagnose MM in a very early stage before surgery.
The identification of such tumour biomarkers might in dept greatly facilitate
surveillance procedures for all the cohorts of patients exposed to asbestos that
will be expected increasing in the next 10–15 years.
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Table S1 Differentially expressed genes in mesothelioma. The
386 genes retrieved by IPA analysis; for each gene is reported the
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